n-hydroxysuccinimide has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buczynski, MW; Burston, JJ; Byrne, F; Chang, JW; Chapman, V; Cognetta, AB; Cravatt, BF; Niphakis, MJ; Parsons, LH | 1 |
| Chae, SY; Kim, K; Lee, KC; Lim, SM; Na, DH; Park, EJ; Son, S | 1 |
2 other study(ies) available for n-hydroxysuccinimide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors.
Topics: Amidohydrolases; Animals; Blood Glucose; Brain; Carbamates; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Evaluation, Preclinical; Endocannabinoids; HEK293 Cells; Humans; Hyperalgesia; Insulin; Liver; Male; Mice; Molecular Structure; Monoacylglycerol Lipases; Nociception; Rats; Rats, Sprague-Dawley; Species Specificity; Structure-Activity Relationship; Succinimides | 2013 |
Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Topics: Animals; Chitosan; Diabetes Mellitus, Type 2; Drug Carriers; Drug Liberation; Exenatide; Hypoglycemic Agents; Lithocholic Acid; Lysine; Mice; Nanoparticles; Particle Size; Peptides; Succinimides; Venoms | 2015 |